|
1.
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Kim VN and Nam JW: Genomics of microRNA.
Trends Genet. 22:165–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Lim LP, Lau NC, Garrett-Engele P, et al:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Bentwich I, Avniel A, Karov Y, et al:
Identification of hundreds of conserved and nonconserved human
microRNAs. Nat Genet. 37:766–770. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Berezikov E, Guryev V, van de Belt J,
Wienholds E, Plasterk RHA and Cuppen E: Phylogenetic shadowing and
computational identification of human microRNA genes. Cell.
120:21–24. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Cheng AM, Byrom MW, Shelton J and Ford LP:
Antisense inhibition of human miRNAs and indications for an
involvement of miRNA in cell growth and apoptosis. Nucleic Acids
Res. 33:1290–1297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Xu P, Guo M and Hay BA: MicroRNAs and the
regulation of cell death. Trends Genet. 20:617–624. 2004.
View Article : Google Scholar
|
|
8.
|
Karp X and Ambros V: Encountering
microRNAs in cell fate signaling. Science. 310:1288–1289. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Chen C-Z, Li L, Lodish HF and Bartel DP:
MicroRNAs modulate hematopoietic lineage differentiation. Science.
303:83–86. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Varambally S, Cao Q, Mani R-S, et al:
Genomic loss of microRNA-101 leads to overexpression of histone
methyltransferase EZH2 in cancer. Science. 322:1695–1699. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Friedman JM, Liang G, Liu C-C, et al: The
putative tumor suppressor microRNA-101 modulates the cancer
epigenome by repressing the polycomb group protein EZH2. Cancer
Res. 69:2623–2629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Anglim PP, Alonzo TA and Laird-Offringa
IA: DNA methylation-based biomarkers for early detection of
non-small cell lung cancer: an update. Mol Cancer. 7:812008.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Barlesi F, Giaccone G, Gallegos-Ruiz MI,
et al: Global histone modifications predict prognosis of resected
non small-cell lung cancer. J Clin Oncol. 25:4358–4364. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Ellinger J, Kahl P, von der Gathen J, et
al: Global levels of histone modifications predict prostate cancer
recurrence. Prostate. 70:61–69. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Varambally S, Dhanasekaran SM, Zhou M, et
al: The polycomb group protein EZH2 is involved in progression of
prostate cancer. Nature. 419:624–629. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Collett K, Eide GE, Arnes J, et al:
Expression of enhancer of zeste homologue 2 is significantly
associated with increased tumor cell proliferation and is a marker
of aggressive breast cancer. Clin Cancer Res. 12:1168–1174. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Vleminckx K, Vakaet L, Mareel M, Fiers W
and van Roy F: Genetic manipulation of E-cadherin expression by
epithelial tumor cells reveals an invasion suppressor role. Cell.
66:107–119. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Semb H and Christofori G: The
tumor-suppressor function of E-cadherin. Am J Hum Genet.
63:1588–1593. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Halbleib JM and Nelson WJ: Cadherins in
development: cell adhesion, sorting, and tissue morphogenesis.
Genes Dev. 20:3199–3214. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Sulzer MA, Leers MP, van Noord JA, Bollen
EC and Theunissen PH: Reduced E-cadherin expression is associated
with increased lymph node metastasis and unfavorable prognosis in
non-small cell lung cancer. Am J Respir Crit Care Med.
157:1319–1323. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Liu D, Huang C, Kameyama K, et al:
E-cadherin expression associated with differentiation and prognosis
in patients with non-small cell lung cancer. Ann Thorac Surg.
71:949–955. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Huang C, Liu D, Masuya D, et al: Clinical
application of biological markers for treatments of resectable
non-small cell lung cancers. Br J Cancer. 92:1231–1239. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Liotta LA, Tryggvason K, Garbisa S, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: biologic activity and
clinical implications. J Clin Oncol. 18:11352000.PubMed/NCBI
|
|
25.
|
Chetty C, Lakka SS, Bhoopathi P and Rao
JS: MMP-2 alters VEGF expression via αVβ3 integrin-mediated
PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer.
127:1081–1095. 2010.
|
|
26.
|
Leinonen T, Pirinen R, Bohm J, Johansson R
and Kosma VM: Increased expression of matrix metalloproteinase-2
(MMP-2) predicts tumour recurrence and unfavourable outcome in
non-small cell lung cancer. Histol Histopathol. 23:693–700.
2008.PubMed/NCBI
|
|
27.
|
Kim S-H, Choi HY, Lee J, et al: Elevated
activities of MMP-2 in the non-tumorous lung tissues of curatively
resected stage I NSCLC patients are associated with tumor
recurrence and a poor survival. J Surg Oncol. 95:337–346. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Hung W-C, Tseng W-L, Shiea J and Chang
H-C: Skp2 overexpression increases the expression of MMP-2 and
MMP-9 and invasion of lung cancer cells. Cancer Lett. 288:156–161.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Polette M, Gilles C, de Bentzmann S,
Gruenert D, Tournier J-M and Birembaut P: Association of
fibroblastoid features with the invasive phenotype in human
bronchial cancer cell lines. Clin Exp Metastasis. 16:105–112. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Miyaki M, Tanaka K, Kikuchi-Yanoshita R,
Muraoka M, Konishi M and Takeichi M: Increased cell-substratum
adhesion, and decreased gelatinase secretion and cell growth,
induced by E-cadherin transfection of human colon carcinoma cells.
Oncogene. 11:2547–2552. 1995.
|
|
31.
|
Nawrocki-Raby B, Gilles C, Polette M, et
al: E-cadherin mediates MMP down-regulation in highly invasive
bronchial tumor cells. Am J Pathol. 163:653–661. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Su H, Yang J-R, Xu T, et al: MicroRNA-101,
down-regulated in hepatocellular carcinoma, promotes apoptosis and
suppresses tumorigenicity. Cancer Res. 69:1135–1142. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Li S, Fu H, Wang Y, et al: MicroRNA-101
regulates expression of the v-fos FBJ murine osteosarcoma viral
oncogene homolog (FOS) oncogene in human hepatocellular carcinoma.
Hepatology. 49:1194–1202. 2009. View Article : Google Scholar
|
|
34.
|
Wang H-J, Ruan H-J, He X-J, et al:
MicroRNA-101 is down-regulated in gastric cancer and involved in
cell migration and invasion. Eur J Cancer. 46:2295–2303. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Strillacci A, Griffoni C, Sansone P, et
al: MiR-101 downregulation is involved in cyclooxygenase-2
overexpression in human colon cancer cells. Exp Cell Res.
315:1439–1447. 2009. View Article : Google Scholar : PubMed/NCBI
|
